Target type: molecularfunction
Enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: Na+(out) + phosphate(out) = Na+(in) + phosphate(in). [TC:2.A.1.14.6]
Sodium:phosphate symporter activity is a transmembrane transport process that couples the movement of sodium ions (Na+) across a cell membrane with the simultaneous movement of inorganic phosphate (Pi) ions. This process is driven by the electrochemical gradient of sodium ions, which are typically at a higher concentration outside the cell than inside.
The symporter protein facilitates the movement of both Na+ and Pi in the same direction, typically from the extracellular space into the cell. This co-transport mechanism is essential for maintaining cellular phosphate homeostasis, which is crucial for a wide range of cellular functions, including:
* **ATP production:** Phosphate is a key component of ATP, the primary energy currency of cells.
* **DNA and RNA synthesis:** Phosphate is a component of nucleotides, the building blocks of DNA and RNA.
* **Signal transduction:** Phosphate plays a crucial role in signal transduction pathways by modifying the activity of proteins through phosphorylation.
* **Bone and teeth formation:** Phosphate is a major constituent of bone and teeth.
Sodium:phosphate symporters are found in a variety of cell types, including intestinal epithelial cells, renal proximal tubule cells, and osteoblasts. These transporters are highly regulated, and their activity can be influenced by factors such as dietary phosphate intake, hormones, and intracellular phosphate levels.
The mechanism of sodium:phosphate symporter activity is complex and involves a series of conformational changes in the protein that allow for the simultaneous binding and transport of Na+ and Pi. The symporter protein is thought to have multiple binding sites for both ions, and the binding of one ion facilitates the binding of the other. Once both ions are bound, the symporter undergoes a conformational change that allows for the movement of both ions across the membrane.
In summary, sodium:phosphate symporter activity is a critical process for maintaining cellular phosphate homeostasis and ensuring the proper functioning of a wide range of cellular processes.'
"
Protein | Definition | Taxonomy |
---|---|---|
Sodium-dependent phosphate transport protein 2B | A sodium-dependent phosphate transport protein 2B that is encoded in the genome of human. [PRO:DNx, UniProtKB:O95436] | Homo sapiens (human) |
Sodium-dependent phosphate transport protein 2B | A sodium-dependent phosphate transport protein 2B that is encoded in the genome of human. [PRO:DNx, UniProtKB:O95436] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
crizotinib | crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER. | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
pf-06463922 | lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein | aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |